<DOC>
	<DOCNO>NCT00041171</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . St. John 's wort may interfere effectiveness chemotherapy . It yet know chemotherapy effective without St. John 's Wort treat solid tumor . PURPOSE : Randomized phase III trial compare effectiveness docetaxel without St. John 's wort treat patient solid tumor remove surgery .</brief_summary>
	<brief_title>Docetaxel St. John 's Wort Treating Patients With Solid Tumors That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect Hypericum perforatum ( St. John 's Wort ) pharmacokinetic clearance docetaxel patient unresectable solid tumor . - Determine effect Hypericum perforatum production plasma concentration M4-C13-hydroxydocetaxel patient . - Determine effect drug pharmacodynamics docetaxel patient . - Determine relationship effect drug docetaxel metabolic clearance CYP3A4/CYP3A5 genotype patient . - Determine relationship effect drug docetaxel metabolic clearance p-glycoprotein genotype patient . - Determine relationship effect drug docetaxel clearance pregnane receptor genotype patient . - Assess compliance drug patient . - Assess steady state concentration hyperforin , one putative psychoactive component Hypericum perforatum , patient . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients receive chronic Hypericum perforatum ( St. John 's Wort ) assign group A , cohort 8 patient receive chronic Hypericum perforatum assign group B . - Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral placebo three time daily day 1-14 docetaxel IV 1 hour day 15 . - Arm II : Patients receive oral Hypericum perforatum three time daily day 1-14 docetaxel arm I . - Group B ( non-randomized group ) : Patients receive docetaxel arm I continue receive chronic regimen Hypericum perforatum except day 15 . Treatment group repeat every 21 day 2 course absence disease progression unacceptable toxicity . Patients follow new primary survival . PROJECTED ACCRUAL : Approximately 92 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable solid tumor , include , limited , follow : Lung cancer Breast cancer Head neck cancer Bladder cancer Prostate cancer Must suitable treatment singleagent docetaxel Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : CTC 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 1.5 time ULN BUN great 1.5 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior docetaxel No 2 prior chemotherapy regimens No concurrent chemotherapy Endocrine therapy : No concurrent hormonal agent except steroid adrenal failure hormone nondiseaserelated condition ( e.g. , insulin diabetes ) Radiotherapy : At least 3 week since prior radiotherapy No concurrent palliative radiotherapy Surgery : At least 4 week since prior major surgery Other : At least 6 month since prior Hypericum perforatum ( St. John 's Wort ) At least 1 week since prior CYP3A enzyme inducer include : Phenobarbital Phenytoin Carbamazepine Lamotrigine Rifampin Rifabutin Isoniazid Sulfinpyrazone Pioglitazone AntiHIV drug efavirenz nevirapine At least 1 week since prior CYP3A enzyme inhibitor include : Erythromycin Clarithromycin Azithromycin Roxithromycin Ketoconazole Fluconazole Itraconazole Metronidazole Chloramphenicol Ritonavir Saquinavir Indinavir Nelfinavir mesylate Delavirdine Amiodarone Cyclosporine Tacrolimus Sirolimus Nefazodone Fluvoxamine No concurrent CYP3A enzyme inducers No concurrent CYP3A enzyme inhibitor No ethanol ( especially red wine ) , grape fruit juice , seville orange juice ( CYP3A enzyme inhibitor ) within 3 day receive docetaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III basal cell carcinoma lip</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage III mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage III esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>